Home > Healthcare > Biotechnology > Biopharma > Cancer Gene Therapy Market

Cancer Gene Therapy Market – By Type (Ex-vivo, In-vivo), Therapy (Oncolytic Virotherapy, Gene-induced Immunotherapy, Gene Transfer), Product (Viral Vectors {Adenoviruses, Lentiviruses}, Non-viral Vectors), End-use, Global Forecast (2024 – 2032)

  • Report ID: GMI763
  • Published Date: Apr 2024
  • Report Format: PDF

Cancer Gene Therapy Market Size

Cancer Gene Therapy Market size was valued at USD 2.2 Billion in 2023 and is expected to reach USD 11.8 Billion by end of 2032, growing at a CAGR of 20.5% over the analysis period, driven by factors such as the rising global prevalence of cancer cases and the growing need for gene therapy.

Cancer Gene Therapy Market

The gene therapy is expected to develop into a viable substitute treatment for neoplastic illnesses and all forms of cancer as a result of recent breakthroughs in the field. For instance, in March 2021, the U.S. FDA approved Abecma (idecabtagene vicleucel), a cell-based gene therapy designated for treating patients with multiple myeloma for patient which had not responded to initial treatment lines.

Cancer gene therapy is a type of treatment that involves using genes to treat or prevent cancer. This approach aims to manipulate the genetic material of cancer cells to inhibit their growth, induce cell death, or stimulate the immune system to target and destroy cancerous cells.

Cancer Gene Therapy Market Trends

  • The rising incidence of cancer cases is projected to create a high demand for novel therapeutic drugs that might prove effective for cancer treatment. As the number of cancer cases rises, there is a greater demand for effective treatment options. Also, cancer gene therapy offers a promising approach by targeting the underlying genetic mechanisms driving cancer or oncology development, thereby providing patients with additional therapeutic options. For instance, in September 2022, the Hadassah Cancer Research Institute (HCRI) announced CancerRNA, a worldwide initiative aimed at advancing the development and utilization of RNA-based immunotherapy to harness anti-cancer immune responses more effectively. Such initiatives associated with cancer therapy is expected to impel the market growth.

Cancer Gene Therapy Market Analysis

Cancer Gene Therapy Market, By Type, 2021 – 2032 (USD Billion)

Based on the type, the market is classified into ex-vivo and in-vivo. The in-vivo segment dominated the market with revenue of USD 1.2 billion in 2023.

  • The development of targeted therapies and personalized medicine approaches is driving the demand for in-vivo cancer gene therapy.
  • Also, in-vivo type of gene delivery systems are being widely used to enhance the expression of immunomodulatory genes or chimeric antigen receptors (CARs) in immune cells, boosting anti-tumor immune responses and improve the efficacy of immunotherapy in cancer patients. Thus, aforementioned factors are expected to accelerate the market growth.
Cancer Gene Therapy Market, By Therapy (2023)

Based on the therapy, the global cancer gene therapy market is classified into oncolytic virotherapy, gene-induced immunotherapy, and gene transfer. The gene-induced immunotherapy dominated the market with revenue of USD 873.7 million in 2023.

  • Gene-induced immunotherapy holds the potential to induce long-term remission or even cure in some cancer patients, which is a significant driver for its adoption in the market.
  • Additionally, advances in gene editing technologies such as CRISPR-Cas9 have revolutionized the field of gene therapy, enabling precise editing of genes associated with cancer immunotherapy. These technological advancements are driving the development of novel gene-induced immunotherapy approaches, thereby augmenting the market growth.

Based on product, the cancer gene therapy market is classified into viral vectors, non-viral vectors, and other products. Viral vectors segment held the highest market share of 46.6% in 2023.

  • Cancer gene therapy is witnessing the emergence of new viral vector platforms beyond traditional vectors such as retroviruses and adenoviruses. Lentiviral vectors, adeno-associated viruses (AAVs), and other engineered viral vectors are being explored for their potential advantages in delivering therapeutic genes to cancer cells.
  • Also, growing interest in combining viral vector-based gene therapies with other treatment modalities, such as chemotherapy, radiation therapy, immunotherapy, and small molecule inhibitors to enhance therapeutic efficacy, overcome treatment resistance, and improve patient outcomes in various cancer types will spur the growth of the market in the coming years.

Based on end-use, the cancer gene therapy market is classified into research institutes, biopharmaceutical companies, and other end-users. The biopharmaceutical companies segment is expected to exhibit 21% CAGR between 2024 - 2032.

  • The market is propelled by the growing utilization of fundamental gene therapy approaches by major biopharmaceutical companies to develop cancer treatment regimens. Moreover, numerous innovative therapeutic medications are undergoing various trial phases, with companies aiming to introduce for wide range of cancer treatment. Therefore, companies with significant product pipeline along with growing incidence of cancer are anticipated to foster the market expansion.
North America Cancer Gene Therapy Market, 2021 – 2032 (USD Million)

In 2023, North America secured a substantial market share of 43.7% in the global cancer gene therapy market and is expected to dominate throughout the forecast period.

  • The factors such as significant investment in research and development, presence of key players, and collaborations between biopharmaceutical companies, research institutions, and healthcare providers are driving the growth of North America market.
  • Also, government agencies such as the National Institutes of Health (NIH) in the U.S. allocate substantial funding to support cancer research, including gene therapy. This funding supports basic research, translational studies, and clinical trials focused on developing and refining gene therapy approaches for various types of cancer.

Cancer Gene Therapy Market Share

The competitive landscape of the market is characterized by the presence of established pharmaceutical companies vying for market share. Key players are engaging in strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their product portfolio. The companies are actively adopting a multi-pronged approaches to address the rising demand for effective cancer gene therapy.

Cancer Gene Therapy Market Companies

Prominent players operating in the cancer gene therapy industry are as mentioned below:

  • Abeona Therapeutics Inc.
  • Altor Bioscience Inc.
  • Asklepios BioPharmaceutical Inc.
  • Bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Elevate Bio
  • Genelux Corporation
  • GSK plc
  • Introgen Therapeutics Inc.
  • Merck KGaA
  • Novartis AG

Cancer Gene Therapy Industry News:

  • In April 2022, GSK plc completed the acquisition of Sierra Oncology, a company engaged in late-stage biopharmaceutical sector. This acquisition aimed to advance GSK's research in rare forms of cancer, particularly focusing on myelofibrosis. Sierra Oncology's key asset, momelotinib, a late-stage therapy with inhibitory properties along vital signaling pathways, addresses unmet medical needs in myelofibrosis patients with anemia. This strategy enabled company to expand its product pipeline development.
  • In June 2021, Eisai and Bristol Myers Squibb entered into a global strategic collaboration agreement for MORAb-202 Antibody Drug Conjugate (ADC). MORAb-202 is Eisai's first ADC, combining Eisai's in-house developed anti-folate receptor alpha (FRα) antibody and anticancer agent eribulin using an enzyme cleavable linker. This collaboration involves joint development and commercialization of MORAb-202 in various territories, including Japan, China, U.S., Europe, Canada, and Russia, thereby strengthening its market presence.

The cancer gene therapy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Type

  • Ex-vivo
  • In-vivo

Market, By Therapy

  • Oncolytic virotherapy
  • Gene-induced immunotherapy
  • Gene transfer

Market, By Product

  • Viral vectors
    • Adenoviruses
    • Lentiviruses
    • Retrovirus
    • Adeno associated virus
    • Herpes simplex virus
    • Vaccinia virus
    • Other viral vectors 
  • Non-viral vectors
  • Other products

Market, By End-use

  • Biopharma companies
  • Research institutes
  • Other end-users

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada 
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • Rest of Asia Pacific
  • Rest of the World


Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global cancer gene therapy market was valued at USD 2.2 billion in 2023 and is expected to reach USD 11.8 billion by end of 2032, driven by rising prevalence of cancer cases and the growing need for gene therapy.

The biopharmaceutical companies segment in the cancer gene therapy industry is expected to exhibit 21% CAGR between 2024 – 2032, propelled by the growing utilization of fundamental gene therapy approaches to develop cancer treatment regimens.

North America cancer gene therapy market secured a substantial share of 43.7% in 2023, attributed to the significant investment in R&D, presence of key players, and collaborations between biopharmaceutical companies, research institutions, and healthcare providers.

Abeona Therapeutics Inc., Altor Bioscience Inc., Asklepios BioPharmaceutical Inc., Bluebird bio, Inc., Bristol-Myers Squibb Company, Elevate Bio, Genelux Corporation, GSK plc, Introgen Therapeutics Inc., Merck KGaA and Novartis AG

Cancer Gene Therapy Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 11
  • Tables & Figures: 256
  • Countries covered: 11
  • Pages: 150
 Download Free Sample